The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company's managerial ...
Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million ...
NexPoint Advisors, L.P. (together with its affiliates "NexPoint") today announced NexPoint Real Estate Opportunities, LLC has submitted a competing proposal to the Board of Trustees of United ...
You won't be able to read Absolute Martian Manhunter by Deniz Camp and Javier Rodriguezdigitally... not properly, anyway.
Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025• APEX trial enrollment in AdvSM patients complete; top-line results ...